Advertisement
< Vol. 84 Issue 3 | Jul-Sep 2017 | pp. 121 - 208

Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future

Abstract

Bladder cancer is the most frequent among the urothelial tumors, and it is responsible for about 2% of all cancer mortality worldwide. The mainstay of chemotherapy treatment, both for muscle-invasive and metastatic disease, is cisplatin-based regimens. In recent years, ground-breaking results have been achieved with immunotherapy, which have led to important breakthroughs in the bladder cancer treatment scenario, with the approval of several new agents. New insights derive from a greater characterization of the tumor genome, which could lead to developing new therapies, more personalized, in the near future.

Urologia 2017; 84(3): 130 - 141

Article Type: REVIEW

DOI:10.5301/uj.5000230

Authors

Gabriella Del Bene, Cora N. Sternberg

Article History

  • • Accepted on 09/03/2017
  • • Available online on 14/06/2017
  • • Published in print on 01/08/2017

Disclosures

Financial support: Cora N. Sternberg had received honoraria or research funding from BMS, Astra Zeneca, Novartis, Merck, Pfizer, Onco-Genyx.
Conflicts of interest: Gabriella Del Bene declared no conflict of interest. This article does not contain any studies with human or animal subjects performed by any of the authors.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  •  Department of Medical Oncology, San Camillo Forlanini Hospital, Padiglione Flajani, Rome - Italy
  •  Department of Experimental Medicine, “La Sapienza” University, Rome - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.